<DOC>
	<DOCNO>NCT02260414</DOCNO>
	<brief_summary>In cancer , incidence venous thromboembolism ( VTE ) particularly high patient myeloma , especially de novo treat thalidomide , lenalidomide erythropoietin . Curiously , prevention VTE LMWH ( low-molecular-weight heparin ) myeloma seem effective achieve aspirin , effectiveness latter primary prevention VTE never demonstrate regardless type population consider . Meanwhile , biological study show prophylactic dos LMWH patient different type cancer always optimal reduction thrombin peak 24 hour follow injection LMWH . These clinical biological study lead conclusion patient myeloma may resistant usual dos preventive LMWH , may explain failure prevention . Initially intend investigate whether resistance prophylactic dos LMWH present patient 's biology resistance specific myeloma hematological cancer . For , propose study evolution thrombin generation Thrombinography 24 hour subcutaneous injection 4500 anti-Xa IU Tinzaparin 6 patient de novo myeloma whit high thrombo embolic risk ie treat thalidomide , lenalidomide erythropoietin . LMWH Tinzaparin chosen accumulate patient impaired renal function , great anti-biological activity thrombotic LMWH . To assess whether observed pattern thrombin generation particularly multiple myeloma , take study 6 patient aggressive lymphoma 6 medical patient hospitalize acute heart respiratory failure .</brief_summary>
	<brief_title>Effects Anticoagulant Preventive Injection Patients With Blood Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Thrombin</mesh_term>
	<mesh_term>Tinzaparin</mesh_term>
	<criteria>1 . Body weight 40 100 kg 2 . Patient : 2a With multiple myeloma indication de novo standard treatment thalidomide lenalidomide erythropoietin ( group 1 ) 2b Or hospitalize aggressive lymphoma treat chemotherapy ( group 2 ) 2c Or old 40 year hospitalize least three day acute medical pathology type acute respiratory cardiac ( group 3 ) decompensation Patient require anticoagulant therapy curative dos Patients low platelet count 80 G / L Subject history heparininduced thrombocytopenia Subject history hemorrhagic disease History severe trauma within 6 week prior enrollment Organic lesion risk bleed Poor renal creatinine clearance &lt; 30 ml / min Hypersensitivity Tinzaparin Events bleed tendency associate coagulation disorder Subject oral anticoagulant For group 3 : Presence hematological malignancy active cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Endogenous Thrombin Potential</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Multiple Myeloma</keyword>
	<keyword>tinzaparin</keyword>
	<keyword>thrombin generation</keyword>
	<keyword>Thromboplastin generation test</keyword>
</DOC>